DK2350316T3 - Fremgangsmåder og anvendelser der involverer genetiske aberrationer af nav3 og aberrerende ekspression af multiple gener - Google Patents

Fremgangsmåder og anvendelser der involverer genetiske aberrationer af nav3 og aberrerende ekspression af multiple gener

Info

Publication number
DK2350316T3
DK2350316T3 DK09821644.3T DK09821644T DK2350316T3 DK 2350316 T3 DK2350316 T3 DK 2350316T3 DK 09821644 T DK09821644 T DK 09821644T DK 2350316 T3 DK2350316 T3 DK 2350316T3
Authority
DK
Denmark
Prior art keywords
aberrative
nav3
expression
methods
applications involving
Prior art date
Application number
DK09821644.3T
Other languages
English (en)
Inventor
Kai Krohn
Annamari Ranki
Emilia Carlsson
Kristian Ovaska
Valtteri Häyry
Sampsa Hautaniemi
Original Assignee
Valipharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valipharma filed Critical Valipharma
Application granted granted Critical
Publication of DK2350316T3 publication Critical patent/DK2350316T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK09821644.3T 2008-10-20 2009-10-19 Fremgangsmåder og anvendelser der involverer genetiske aberrationer af nav3 og aberrerende ekspression af multiple gener DK2350316T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19676108P 2008-10-20 2008-10-20
PCT/FI2009/050838 WO2010046530A1 (en) 2008-10-20 2009-10-19 Methods and uses involving genetic aberrations of nav3 and aberrant expression of multiple genes

Publications (1)

Publication Number Publication Date
DK2350316T3 true DK2350316T3 (da) 2014-05-05

Family

ID=42118980

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09821644.3T DK2350316T3 (da) 2008-10-20 2009-10-19 Fremgangsmåder og anvendelser der involverer genetiske aberrationer af nav3 og aberrerende ekspression af multiple gener

Country Status (12)

Country Link
US (2) US20120058108A1 (da)
EP (1) EP2350316B1 (da)
JP (1) JP5819728B2 (da)
AU (1) AU2009306260B2 (da)
CA (1) CA2740351A1 (da)
CY (1) CY1115258T1 (da)
DK (1) DK2350316T3 (da)
ES (1) ES2469802T3 (da)
PL (1) PL2350316T3 (da)
PT (1) PT2350316E (da)
SI (1) SI2350316T1 (da)
WO (1) WO2010046530A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2598659T3 (da) 2010-07-27 2015-05-26 Genomic Health Inc Fremgangsmåde til anvendelse af genekspression til bestemmelse af prognose for prostatacancer
HK1199099A1 (en) * 2011-08-31 2015-06-19 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of cancer
CN110890128B (zh) * 2018-09-10 2024-02-09 立森印迹诊断技术（无锡）有限公司 一种用于检测皮肤肿瘤良恶性程度的分级模型及其应用
EP4481745A4 (en) * 2022-02-18 2026-02-18 Riken METHOD FOR PERFORMING PHYLOGENETIC CELL ANALYSIS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
DE19728737C1 (de) * 1997-07-04 1999-02-11 Johannes Christian Groeninghen Verfahren zur Erkennung und Bestimmung von GnRH-Rezeptoren und die Verwendung von GnRH-Agonisten und GnRH-Antagonisten zur Behandlung eines Tumors ausgehend vom Hirn und/oder Nervensystem und/oder den Hirnhäuten
US7834141B1 (en) * 2000-03-31 2010-11-16 Theresa Siler-Khodr Non-mammalian GnRH analogs and uses thereof in tumor cell growth regulation and cancer therapy
DE10292896D2 (de) * 2001-07-05 2004-07-01 Univ Goettingen Georg August Gentherapeutisches Verfahren zur Behandlung von GnRH-Rezeptor-positiven Karzinomen durch GnRH induzierte tumorzellspezifische Aktivierung eines therapeutischen Gens, zugehörige Nukleinsäurekonstrukte und Vektoren
FI113666B (fi) * 2002-01-24 2004-05-31 Tapio Visakorpi Menetelmiä, joissa käytetään kromosomin 12 spesifisiä katkoskohtia ja/tai neuroninavigaattori 3 -geeniä ihon primaaristen T-solulymfoomien diagnosoimiseksi ja taudin etenemisen seuraamiseksi tai ennustamiseksi, sekä näiden katkoskohtien ja geenien käyttö
WO2004021010A2 (en) * 2002-08-30 2004-03-11 Oncotherapy Science, Inc. Method of diagnosing colon and gastric cancers
ATE440864T1 (de) * 2003-03-10 2009-09-15 Schering Corp Verwendung von il-23-antagonisten; verwandte reagenzien
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
SG142186A1 (en) * 2006-10-20 2008-05-28 Agency Science Tech & Res Breast tumour grading
PL2092081T3 (pl) * 2006-11-13 2013-07-31 Valipharma Sposoby i zastosowania obejmujące genetyczne nieprawidłowości w chromosomie 12

Also Published As

Publication number Publication date
AU2009306260A1 (en) 2010-04-29
PT2350316E (pt) 2014-06-23
PL2350316T3 (pl) 2014-10-31
JP2012505666A (ja) 2012-03-08
AU2009306260B2 (en) 2015-12-24
CY1115258T1 (el) 2017-01-04
WO2010046530A1 (en) 2010-04-29
EP2350316A4 (en) 2012-05-30
CA2740351A1 (en) 2010-04-29
US20120058108A1 (en) 2012-03-08
SI2350316T1 (sl) 2014-09-30
WO2010046530A8 (en) 2010-07-15
JP5819728B2 (ja) 2015-11-24
US20160083798A1 (en) 2016-03-24
ES2469802T3 (es) 2014-06-20
EP2350316A1 (en) 2011-08-03
EP2350316B1 (en) 2014-04-16

Similar Documents

Publication Publication Date Title
DK2104739T3 (da) Modificerede messenger-RNA-stabiliseringssekvenser til ekspression af gener i bakterieceller
LTC2059534I2 (lt) Genų inžinerijos būdu pagaminti anti-IL-23P19 antikūnai
DK2170403T3 (da) Sammensætninger og fremgangsmåder til hæmning af ekspressionen af proapoptotiske gener
DK2660333T3 (da) Nicking- og forlængelsesamplifikationsreaktion til exponentiel amplifikation af nucleinsyrer
DK2558579T3 (da) Capping-tilbøjelige rna-polymeraseenzymer og anvendelser deraf
DK2574677T3 (da) Fremgangsmåder til celledyrkning
DK2424571T3 (da) Genvektor
EP2603201A4 (en) LIPOSOME COMPOSITIONS AND USE METHOD THEREFOR
EP2294200A4 (en) NEW BIOSYNTHESIS GENES
BRPI0906672A2 (pt) Microorganismos transgênicos fotossintéticos e fotobiorreator
DK2318028T3 (da) Antagonister af opløselig activin-aktriia og anvendelser til øgning af røde blodcelleniveauer
DK3587579T3 (da) Fremgangsmåder og sammensætninger til specifik hæmning af beta-catenin ved hjælp af dobbeltstrenget rna
DK2638064T3 (da) Celledyrkningsmedie og fremgangsmåde til proteinekspression, hvilket medie og hvilken fremgangsmåde omfatter en PAM inhibitor
PL2800811T3 (pl) Sposoby i kompozycje do kierowanej RNA modyfikacji docelowego DNA i do modulacji transkrypcji kierowanej RNA
EP2596017A4 (en) Cross-protective pathogen protection, methods and compositions thereof
DK3428290T3 (da) Sammensætninger og fremgangsmåder til amplifikation af nukleinsyrer
DK3243910T3 (da) Bestemmelse af progrediering af kromosomafvigelser i en organisme
EP2389352A4 (en) ARGINE STARTER AND USE METHOD
EP2356462A4 (en) ANTI-CXCR1 COMPOSITIONS AND METHOD
DK3012329T3 (da) Fremgangsmåder og materialer til at vurdere tab af heterozygositet
DK3597761T3 (da) Prostatacancercellelinjer, gensignaturer og anvendelser deraf
IL212570A0 (en) Composiitons and methods for inhibiting expression of factor vii genes
BRPI0816776A2 (pt) métodos para usar marcadores genéticos e interações epistáticas relacionadas
EP2461806A4 (en) SMALL ANTIANGIOGENIC MOLECULES AND METHOD OF USE THEREOF
EP2328404A4 (en) RESISTANCE GENE